Customize your JAMA Network experience by selecting one or more topics from the list below.
Ozer E, Grecula JC, Agrawal A, Rhoades CA, Schuller DE. Intensification Regimen for Advanced-Stage Resectable Hypopharyngeal Carcinoma. Arch Otolaryngol Head Neck Surg. 2006;132(4):385–389. doi:10.1001/archotol.132.4.385
To determine feasibility, compliance, long-term survival, and disease control rates in the intensification regimen for advanced resectable hypopharyngeal carcinoma.
Prospective, nonrandomized, controlled phase 2 trial with a median follow-up period of 89 months (range, 3.4-140.0 months).
Cancer center at a state university.
Thirty-two patients (age range, 44-79 years; median age, 59 years) with advanced (69% stage IV, 31% stage III) resectable hypopharyngeal carcinoma.
Combination of surgery, radiation therapy, and chemotherapy (cisplatin and paclitaxel) along with intraoperative radiation therapy.
Main Outcome Measures
Compliance, long-term survival, and locoregional and systemic disease control rates and functional outcome.
The protocol compliance rate was 62% (20 of 32 patients), and the overall 5-year survival rate was 56%. Local recurrence occurred in 3 patients (9%). The systemic disease control rate was 91% (29 of 32 patients). Total laryngectomy was required in 15 patients (47%); preservation of the larynx was possible in 17 patients (53%). Only 3 (13%) of 6 patients were percutaneous endoscopic gastrostomy tube dependent in the long-term follow-up.
The intensification regimen described in this study accomplished excellent long-term survival and disease control rates in patients with advanced resectable hypopharyngeal carcinoma. The future plan is to proceed with a phase 3 trial if the single-institutional experience at The Ohio State University can be duplicated in a multi-institutional phase 2 study.
Create a personal account or sign in to: